General Biologicals Corporation (TPEX:4117)
Taiwan · Delayed Price · Currency is TWD 10.50
0.00 (0.00%)
Jul 9, 2026, 2:59 PM CST
General Biologicals Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 465.84 | -220.82 | -198.83 | -53.19 | 44.14 |
Depreciation & Amortization | 78.77 | 37.6 | 36.04 | 35.18 | 34.97 |
Other Amortization | 0.31 | 0.43 | 0.64 | 0.74 | 0.76 |
Loss (Gain) From Sale of Assets | -748.16 | - | - | 0.38 | -9.85 |
Loss (Gain) From Sale of Investments | 2.91 | -3.05 | -4.89 | -0.44 | 5.82 |
Loss (Gain) on Equity Investments | -0.01 | 0.25 | 6.93 | 1.34 | 0.16 |
Stock-Based Compensation | 12.57 | 10.8 | - | - | - |
Provision & Write-off of Bad Debts | 0.75 | 2.64 | -3.88 | -3.71 | -15.74 |
Other Operating Activities | -16.43 | 3.62 | 16.01 | 16.51 | -5.54 |
Change in Accounts Receivable | 11.13 | -65.02 | 25.81 | -14.91 | 33.32 |
Change in Inventory | -1.88 | 30.93 | 31.24 | -35.47 | -18.48 |
Change in Accounts Payable | 3.32 | 59.52 | -0.79 | -10.01 | -1.63 |
Change in Unearned Revenue | 17.65 | 24.43 | 0.66 | 1.51 | -3.78 |
Change in Other Net Operating Assets | 45.98 | -71.02 | 316.75 | 287.08 | -10.18 |
Operating Cash Flow | -127.26 | -189.68 | 225.68 | 225.01 | 38.97 |
Operating Cash Flow Growth | - | - | 0.30% | 477.34% | -16.62% |
Capital Expenditures | -180.02 | -1,545 | -424.02 | -248.42 | -14.73 |
Sale of Property, Plant & Equipment | - | - | - | 2.19 | 1.51 |
Cash Acquisitions | - | -0.92 | - | - | - |
Divestitures | -5.61 | - | - | - | - |
Sale (Purchase) of Intangibles | -0.45 | -0.85 | -1 | -0.18 | -2.59 |
Investment in Securities | - | - | 88.9 | -29.65 | 59.04 |
Other Investing Activities | 2.15 | -8.24 | -6.19 | -1.84 | -118.98 |
Investing Cash Flow | -183.92 | -1,555 | -342.31 | -277.91 | -75.76 |
Short-Term Debt Issued | 150 | 150 | 50 | 5 | - |
Long-Term Debt Issued | 345.89 | 1,718 | 35 | - | 5 |
Total Debt Issued | 495.89 | 1,868 | 85 | 5 | 5 |
Short-Term Debt Repaid | -150 | -140 | -5 | - | - |
Long-Term Debt Repaid | -177.79 | -21.99 | -7.63 | -14.74 | -9.26 |
Total Debt Repaid | -327.79 | -161.99 | -12.63 | -14.74 | -9.26 |
Net Debt Issued (Repaid) | 168.11 | 1,706 | 72.37 | -9.74 | -4.26 |
Issuance of Common Stock | 120 | - | - | - | - |
Other Financing Activities | 19.34 | - | - | - | - |
Financing Cash Flow | 307.45 | 1,706 | 72.37 | -9.74 | -4.26 |
Foreign Exchange Rate Adjustments | -4.56 | 73.5 | -0.81 | 16.05 | -0.79 |
Net Cash Flow | -8.3 | 34.52 | -45.06 | -46.59 | -41.83 |
Free Cash Flow | -307.28 | -1,735 | -198.33 | -23.42 | 24.24 |
Free Cash Flow Growth | - | - | - | - | 3.23% |
Free Cash Flow Margin | -142.43% | -688.57% | -74.89% | -6.32% | 4.40% |
Free Cash Flow Per Share | -4.91 | -29.00 | -3.31 | -0.39 | 0.41 |
Cash Interest Paid | 30.88 | 8.46 | 7.14 | 7.32 | 11 |
Levered Free Cash Flow | -108.3 | -2,334 | 291.73 | -291.83 | 27.32 |
Unlevered Free Cash Flow | -82.18 | -2,325 | 299.22 | -281.29 | 34.19 |
Change in Working Capital | 76.2 | -21.15 | 373.67 | 228.19 | -15.76 |